Share Email Print

Proceedings Paper

Novel visible light activated type 1 photosensitizers
Author(s): Raghavan Rajagopalan; Amolkumar Karwa; Amruta R. Poreddy; Przemyslaw M. Lusiak; Raghoottama S. Pandurangi; Gary L. Cantrell; Richard B. Dorshow
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Photodynamic therapy of tumors involving Type 2 photosenstizers has been conspicuously successful, but the Type 1 process, in contrast, has not received much attention despite its considerable potential. Accordingly, several classes of molecules containing fragile bonds such as azido (-N=N=N), azo (-N=N-), and oxaza (-N-O-) functional groups that produce reactive intermediates such as radicals and nitrenes upon photoexcitation with visible light were prepared and tested for cell viability using U397 leukemia cell line. The cells were incubated with the photosensitizer at various concentrations, and were illuminated for 5, 10, and 20 minutes. The results show that all the photosensitizers caused cell death compared to the controls when exposed to both the photosensitizers and light.

Paper Details

Date Published: 2 March 2010
PDF: 6 pages
Proc. SPIE 7551, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX, 75510R (2 March 2010); doi: 10.1117/12.844970
Show Author Affiliations
Raghavan Rajagopalan, Covidien Pharmaceuticals (United States)
Amolkumar Karwa, Covidien Pharmaceuticals (United States)
Amruta R. Poreddy, Covidien Pharmaceuticals (United States)
Przemyslaw M. Lusiak, Covidien Pharmaceuticals (United States)
Raghoottama S. Pandurangi, Covidien Pharmaceuticals (United States)
Gary L. Cantrell, Covidien Pharmaceuticals (United States)
Richard B. Dorshow, Covidien Pharmaceuticals (United States)

Published in SPIE Proceedings Vol. 7551:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XIX
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?